Skip to main content

Table 4 Outcome data

From: Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

  Group A
ASA alone
%(n = 106)
Group B
Ticagrelor +ASA
%(n = 55)
p-Value
Time in intensive care unit (hrs) 93 ± 70 70 ± 24 0.005
Ventilation time (hrs) 13 ± 13 15 ± 16 0.990
Intraaortic balloon pump (%, n) 2 (2) 4 (2) 0.608
Post operative discharge day 8.3 ± 8.1 7.3 ± 4.6 0.552
Lowest Hemoglobin (gr/dl) 8.6 ± 1.2 8.4 ± 0.9 0.028
Δ Hemoglobin (gr/dl) 2.7 ± 1.3 2.5 ± 1.3 0.804
Chest drainage volume (ml)
 Day 1 569 ± 393 649 ± 427 0.854
 Total volume 1477 ± 1012 1454 ± 715 0.086
Blood products infused (units)
 Red blood packed cells 1.2 ± 1.6 1.3 ± 1.3 0.576
 Fresh frozen plasma 0.5 ± 1.2 0.4 ± 1 0.112
 Cryoprecipitate 0.2 ± 1.4 0.1 ± 0.8 0.420
 Platelets 2.3 ± 3.8 2.4 ± 3.4 0.547
Complications (n,%)
 Bleeding requiring surgical re-exploration 0 0 NS
 Neurologic (incl. stroke) 1 (1) 0 (0) NS
 Pneumonia 4 (4) 5 (3) 0.692
 Infection (any) 5 (5) 10 (5) 0.316
 Renal failure 10 (10) 2 (1) 0.099
  Requiring dialysis 0 0 NS
  Discharged with dialysis 0 0 NS
 Atrial fibrillation 38 (40) 22 (12) 0.035
 Permanent pacemaker 0 (0) 2 (1) NS
 Gastrointestinal 0 0 NS
Primary End Point
 (RBC > 1000 cc, drainage≥2000 cc, or Revision) 26 (28) 27 (15) NS
  1. Values are given as mean + SD